Juq-097 〈TOP ◎〉

| Area | Open Question | Planned/Proposed Study | |------|---------------|------------------------| | | Does NOP antagonism reduce opioid or stimulant relapse? | Phase IIb exploratory arm in opioid‑use disorder (OUD) slated for 2027. | | Neuroimaging biomarkers | Which brain circuits show occupancy‑linked changes? | PET ligand (NOP‑specific) study using [¹⁸F]‑JNJ‑54175446, recruiting 30 AUD patients (2026). | | Precision medicine | Are there genetic polymorphisms (OPRL1) that predict response? | Genome‑wide association sub‑analysis of Phase II data. | | Long‑term safety | Effects beyond 12 months, especially on mood and cognition? | Open‑label extension (OLE) up to 24 months (ongoing). | | Combination with Naltrexone | Additive or synergistic anti‑craving? | Small‑scale crossover trial (n = 40) planned for late 2026. |

(assumed) Product / Component / Model number — write-up covers purpose, specs, usage, troubleshooting, and procurement. JUQ-097

Note: The granted Fast‑Track designation (Sept 2024) and Breakthrough Therapy status (Jan 2025) based on Phase Ib data. | Area | Open Question | Planned/Proposed Study

JUQ-097 remains an enigma, a puzzle waiting to be solved. Its significance, whether it pertains to a scientific breakthrough, a technological innovation, or a theoretical advancement, underscores the complexity and richness of scientific research. As more information becomes available, it is likely that JUQ-097 will shed its mysterious aura, revealing its true nature and contributions to human knowledge. Until then, the designation serves as a reminder of the ongoing quest for understanding and the boundless potential of scientific inquiry. | | Long‑term safety | Effects beyond 12